You are now leaving Lundbeck.com/sg/en.

Cancel

Lundbeck is planning to transition its commercial operations in Singapore to be managed by Zuellig Pharma per 1 December, 2025.

For more information, we refer to Lundbeck's press release.

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our science

A better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person and community behind the disease. 

Our focus

Our sustainability strategy

Through our sustainability strategy, we mitigate business risks, reduce negative impacts, and address societal challenges where possible. We remain committed to UN Global Compact Principles, and contribute to seven of the 17 UN Sustainable Development Goals.

Read more

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Mara Formentini on working at Lundbeck

Bringing your whole self to work and its rewards  

See all stories

Lundbeck at a glance